Nagarjuna Reddy Gujjula, MD
Cardiovascular Disease · Richland, WANPI 1316329139
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,254 of the $14,199 with a category attached, or 65.2%. Medtronic accounts for 65.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $7,053 and has fallen 93.0% since, to $495 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $144.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Boston Scientific$2K
- Abbott$1K
- Abiomed$487
- Chiesi USA, Inc.$170
- Boehringer Ingelheim$137
- plus $466 from 10 others
What the payments were for
- Travel & lodging$9,25465%
- Food & beverage$4,94535%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 34 | $9,250 |
| Boston Scientific | 18 | $2,279 |
| Abbott | 15 | $1,408 |
| Abiomed | 7 | $487 |
| Chiesi USA, Inc. | 3 | $170 |
| Boehringer Ingelheim | 2 | $137 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $135 |
| Cardiovascular Systems Inc. | 1 | $124 |
| Amgen | 4 | $63 |
| Johnson & Johnson | 2 | $33 |
| Edwards Lifesciences | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Terumo Medical Corporation | 1 | $17 |
| Novartis | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$1,645
- MitraClip$419
- Impella$250
- AVVIGO Guidance System$233
- Merlin Connectivity and Remote$175
- CentriMag$171
- Assurity Pacemaker$164
- HeartMate 3 Left Ventricular Assist Device$143
- KENGREAL 50MG/10ML L$140
- SYMPLICITY G3$130
- Diamondback Coronary$124
- Watchman$121
- JARDIANCE$116
- CROSSBOSS$116
- OPTIS$112
- GUIDEZILLA$107
How this compares
$14,199 in reported general payments places this provider in the 90th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 231 | $288,794 |
| EliquisApixaban | 179 | $238,230 |
| EntrestoSacubitril/Valsartan | 84 | $95,295 |
| XareltoRivaroxaban | 26 | $34,098 |
| FarxigaDapagliflozin Propanediol | 24 | $32,852 |
| Repatha SureclickEvolocumab | 18 | $16,758 |
| BrilintaTicagrelor | 21 | $13,763 |
| Metoprolol Succinate | 647 | $11,890 |
| Ranolazine ErRanolazine | 42 | $3,981 |
| ClopidogrelClopidogrel Bisulfate | 222 | $3,771 |
| Atorvastatin Calcium | 338 | $3,591 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 142 | $3,046 |
| Ezetimibe | 126 | $2,858 |
| Rosuvastatin Calcium | 123 | $2,107 |
| Losartan Potassium | 216 | $2,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $137 | $288,794231 claims |
| PfizerEliquis | $13 | $238,230179 claims |
| NovartisEntresto | $13 | $95,29584 claims |
| Johnson & JohnsonXarelto | $33 | $34,09826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Richland
- Munish Kumar KannabhiranRichland$85K
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Thomas AmidonBellevue$64K
- Aron BenderSeattle$60K
- Vidhushei YogeswaranSeattle$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.